MedTrace Logo

Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC

NCT05065346 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2024-05-17

No results posted yet for this study

Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device (DaRT) as a treatment prior to additional radiation or chemo therapy.

Conditions

Interventions

DEVICE

Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT

An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    collaborator NETWORK

  • Alpha Tau Medical LTD.

    lead INDUSTRY

Principal Investigators

  • Aron Popovtzer, MD · Sharett institute, Hadassah Medical Center - Ein-Kerem

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05065346 on ClinicalTrials.gov